title: Current and emerging therapies in osteoporosis.
abstract: Osteoporosis is a systemic skeletal disorder leading to decreased bone mineralisation and a propensity for fracture. The disease affects millions of people and is a source of significant morbidity and mortality. Fracture-related costs have skyrocketed in recent years and projections suggest an increase as the population ages. Recent advances in the understanding of bone biology have improved the therapeutic options for osteoporosis. This is a review of the osteoporotic therapies that have recently become available and a discussion of emerging options. An overview on current practice guidelines is provided.
authors.affiliation: Division of Endocrinology, Molecular Medicine and Metabolism, Northwestern University Medical School, Tarry Building 14-759, 303 East Chicago Avenue, Chicago, Illinois 60611, USA. a-desantis@northwestern.edu
authors.forename: Anthony
authors.initials: A
authors.lastname: DeSantis
authors.forename: Alan
authors.initials: A
authors.lastname: Buchman
mesh_terms: D015502:Absorptiometry, Photon; D000375:Aging / Q000473:pathology; D002116:Calcitonin / Q000627:therapeutic use; D002118:Calcium / Q000008:administration & dosage / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004164:Diphosphonates / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D020847:Estrogen Receptor Modulators / Q000627:therapeutic use; D015914:Estrogen Replacement Therapy; D005260:Female; D005459:Fluorides / Q000627:therapeutic use; D006801:Humans; D008297:Male; D010024:Osteoporosis / Q000175:diagnosis / Q000188:drug therapy*; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy; D017410:Practice Guidelines as Topic
chemical_list: D004164:Diphosphonates; D020847:Estrogen Receptor Modulators; D002116:Calcitonin; D005459:Fluorides; D002118:Calcium